STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

News
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Rhea-AI Summary
Merck (MRK) initiates pivotal Phase 3 trials for four investigational candidates in hematologic malignancies and solid tumors, including bomedemstat, nemtabrutinib, MK-2870, and MK-5684. The trials demonstrate the company's commitment to research across novel mechanisms of action in various cancers, such as lung, endometrial, and prostate cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
clinical trial
-
News
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Merck (NYSE: MRK) announced the participation of Robert M. Davis and Dr. Dean Y. Li in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024. The event will be live webcasted for investors, analysts, media, and the general public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences
-
News
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Rhea-AI Summary
Daiichi Sankyo (4568) and Merck (MRK) announce FDA Priority Review for patritumab deruxtecan (HER3-DXd) for EGFR-mutated non-small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
News
Merck Provides U.S. Regulatory Update on Gefapixant
Rhea-AI Summary
Merck (MRK) receives Complete Response Letter from FDA for gefapixant NDA, citing lack of substantial evidence for effectiveness in treating refractory chronic cough (RCC) and unexplained chronic cough (UCC) in adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
News
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
Rhea-AI Summary
Merck (NYSE: MRK) CEO to participate in fireside chat at Goldman Sachs Healthcare C-Suite Unscripted Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
conferences
-
News
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
Rhea-AI Summary
Merck (MRK) announces FDA acceptance for priority review of V116, a 21-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
News
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
Rhea-AI Summary
Merck (MRK) has received approval from the European Commission for two new indications for KEYTRUDA, their anti-PD-1 therapy, in gastrointestinal cancers. The approvals are based on positive Phase 3 trial results from KEYNOTE-859 and KEYNOTE-966, showing significant improvement in overall survival rates. These approvals bring the total number of KEYTRUDA indications in the EU to 26, with seven in gastrointestinal cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
News
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
Rhea-AI Summary
Merck (MRK) has received FDA approval for KEYTRUDA, its anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv), for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The approval is based on the results of the Phase 3 KEYNOTE-A39 trial, demonstrating a superior overall survival benefit with KEYTRUDA plus Padcev versus platinum-based chemotherapy. The approval expands the use of KEYTRUDA plus Padcev for locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility. The approval came nearly five months ahead of the PDUFA goal date of May 9, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
Rhea-AI Summary
Merck (MRK) receives FDA approval for WELIREG, the first HIF-2α inhibitor for advanced RCC patients. The approval is based on statistically significant results from LITESPARK-005, demonstrating superior progression-free survival and objective response rate compared to everolimus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
fda approval
News
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
Rhea-AI Summary
Moderna, Inc. (MRNA) and Merck (MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, showing that mRNA-4157 in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection. The companies have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
Stock MRK logo
Merck & Co Inc

NYSE:MRK

MRK Rankings

#25 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1283 Ranked by Dividends

MRK Stock Data

318.50B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.